[Retracted] Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study

Table 1

Comparison of clinical baseline data [].

	Group 2a ()	Group 2b ()
Age (years, )			0.667	0.507
Gender []			0.441	0.507
Male	23 (54.76)	26 (61.90)
Female	19 (45.24)	16 (38.10)
Family history of illness []			0.124	0.724
Have	4 (9.52)	5 (11.90)
Without	38 (90.48)	37 (88.10)
History of liver disease []			0.081	0.776
Have	8 (19.05)	7 (16.67)
Without	34 (80.95)	35 (83.33)
History of diabetes []			0.223	0.637
Have	12 (28.57)	14 (33.33)
Without	30 (71.43)	28 (66.67)
History of hypertension []			0.214	0.643
Have	15 (35.71)	13 (30.95)
Without	27 (64.29)	29 (69.05)
Smoking []			0.449	0.503
Yes	18 (42.86)	15 (35.71)
No	24 (57.14)	27 (64.29)
Drinking []			—	—
Yes	15 (35.71)	15 (35.71)
No	27 (64.29)	27 (64.29)
Living environment []			0.343	0.558
City	34 (80.95)	36 (85.71)
Countryside	8 (19.05)	6 (14.29)